Trial Profile
Evaluate immunogenicity, reactogenicity and safety of 2 doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated HRV [human rotavirus] vaccine (RIX4414 at 10exp6.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary) ; Poliovirus vaccine live oral
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GSK
- 25 Feb 2009 Results were published in Vaccine in Feb 2009.
- 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
- 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.